Vaccine Trial Centre: rAcellular Pertussis Vaccine Project Timeline



2015
Safety and Efficacy to demonstrate non-inferior immunogenicity of a combined Tetanus-diphtheria-acellular Pertussis vaccine as compared To Adacel vaccine in healthy aged 12-17 years (TDA202)
Licensed
2017
Antibody persistence at 2 years After a single does vaccination Of acellular pertussis vaccines among Thai adolescents (TDA202 2 year follow up)
2018
Antibody persistence at 3 years After a single does vaccination of acellular pertussis vaccines Containing genetically-detoxified pertussis toxin (TDA202 3 year follow up)
2019
Safety and Immunogenicity
of a licensed tetanus-diphtheria-recombinant
acellular pertussis vaccine and pediatric
diphtheria-tetanus-recombinant aP vaccine when administered to healthy children
Aged 3-7 years (DTA101)
2020
- Antibody persistence at 5 years after a single Dose vaccination of acellular pertussis vaccines containing genetically-inactivated pertussis toxin (TDA202 5 year follow up)
- A PhaseII/III randomized, observer-blind, active-controlled study to compare non-inferior immunogenicity of a combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (non-recombinant), when administered to healty toddlers aged of 15-36 months old (DTA201)